Industry's No 1 Immunogenicity Event: Discover the latest technologies, regulations and trends shaping the detection, management and prediction of immunogenicity before and during clinical trials

Full list of speakers:

• Dr Eric Wakshall, Group Leader, Senior Scientist, Genentech, USA
• Dr Michael Tovey, Director, Laboratory of Viral Oncology, Institute Andre Lwoff, France
• Dr Dong Geng, Director, Regeneron, USA
• Dr Daniel Kramer, Corporate Expert Immunogenicity, Merck Serono, Germany
• Dr Theo Rispins, Sanquin, The Netherlands
• Dr Stephen Ulrich, Senior Scientist II, Clinical Immunology, Human Genome Sciences, USA
• Dr Robin Thorpe, Head of Biotherapeutics Group, NIBSC, UK
• Dr Lakshmi Amaravadi, Director, Clinical Science & Technology, BiogenIdec, USA
• Dr Stefan Kostense, Associate Director Clinical Assays, GLP Facility Manager, Crucell Holland BV, The Netherlands
• Dr Nadja S Prang-Richard, BioChallenges Consulting SARL, France
• Dr Matthew Baker, Chief Scientific Officer, R&D , Antitope, UK
• Professor Roy Jefferis, Professor Emeritus: Molecular Immunology, School of Immunity & Infection, University of Birmingham, UK
• Dr Joel Richard, Senior Director, Head of Drug Product Development, Pharmaceutical Development, Ipsen, France
• Dr Julia Schleypen, Head of Protein Bioanalytics Development, Roche Diagnostics, Germany
• Dr Helen Loughrey, Director, Immunology and Formulation Development, Theratechnologies, Canada
• Dr Lorella Di Donato, VP Analytical Operations, CIRION Biopharma Research Inc, Canada 
• Dr Robert Umek, Director, Research and Critical Reagents, MSD
• Dr Jorgen Dahlstrom, Scientific Director, Phadia, Sweden
• Dr Houston Gilbert, Biostatistian, Non Clinical Biostatistics, Genentech, USA